HOUSTON, Aug. 15, 2019 /PRNewswire/
-- Marker Therapeutics, Inc. (Nasdaq:MRKR), a
clinical-stage immuno-oncology company specializing in the
development of next-generation T cell-based immunotherapies for the
treatment of hematological malignancies and solid tumor
indications, today announced the appointment of Nadia Agopyan, Ph.D., RAC as Vice President of
Regulatory Affairs, effective August
15.
"We are pleased to welcome a professional of Nadia's caliber and
senior leadership experience to Marker," said Peter L. Hoang, President & CEO of Marker.
"With more than 15 years of industry knowledge in regulatory
affairs and clinical development, Nadia will be instrumental in
helping shape our regulatory strategy as we prepare to initiate the
first Marker-sponsored trial with MultiTAA therapy in patients with
post-transplant acute myeloid leukemia."
Dr. Agopyan joins Marker from Kite Pharma, a subsidiary of
Gilead Sciences, where she served as Director of Regulatory
Affairs, Global Regulatory Lead. In this role, she was responsible
for overseeing the global marketing authorization and lifecycle
management of the YESCARTA® franchise, defining the global
regulatory strategies for CAR T cell products in lymphoma/leukemia,
and overseeing clinical programs from Phase 1-4 development, as
well as all operational aspects of global regulatory submissions.
Previously, she served as Global Regulatory Lead at Baxter
Biosciences leading Vonvendi (recombinant von Willebrand Factor)
approval/launch, Senior Director Regulatory Affairs at Ambit
Biosciences, and Director Regulatory Affairs at Cougar
Biotechnology, a unit of Johnson
and Johnson Ortho Biotech Oncology, where she led the approval of
Zytiga, abiraterone acetate, for the treatment of patients with
metastatic castrate-resistant prostate cancer.
Earlier in her career, Dr. Agopyan served in various roles at
biotechnology companies such as Amgen, CATO Research and Allelix
Biopharmaceuticals and as Assistant Professor in academia including
Duke University and University of Toronto.
Dr. Agopyan earned her Ph.D. and B.Sc. in Neurophysiology from
McGill University (Montreal Canada).
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in
the development of next-generation T cell-based immunotherapies for
the treatment of hematological malignancies and solid tumor
indications. Marker's cell therapy technology is based on the
selective expansion of non-engineered, tumor-specific T cells that
recognize tumor associated antigens (i.e. tumor targets) and kill
tumor cells expressing those targets. This population of T cells is
designed to attack multiple tumor targets following infusion into
patients and to activate the patient's immune system to produce
broad spectrum anti-tumor activity. Because Marker does not
genetically engineer its T cells therapies, we believe that our
product candidates will be easier and less expensive to
manufacture, with reduced toxicities, compared to current
engineered CAR-T and TCR-based approaches, and may provide patients
with meaningful clinical benefit. As a result, Marker believes its
portfolio of T cell therapies has a compelling product profile, as
compared to current gene-modified CAR-T and TCR-based
therapies.
Marker is also advancing a number of innovative peptide- and
gene-based immuno-therapeutics for the treatment of metastatic
solid tumors, including the Folate Receptor Alpha program (TPIV200)
for breast and ovarian cancers and the HER2/neu program
(TPIV100/110) for breast cancer, currently in Phase 2 clinical
trials.
To receive future press releases via email, please
visit: https://markertherapeutics.com/email-alerts/
Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements in this news release concerning the
Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made
or expectations as to any future events, conditions, performance or
other matters, are "forward-looking statements." Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: our research, development and regulatory
activities and expectations relating to our non-engineered
multi-tumor antigen specific T cell therapies; our TPIV200 and
TPIV100/110 programs; the effectiveness of these programs or the
possible range of application and potential curative effects and
safety in the treatment of diseases; and, the timing and success of
our clinical trials, as well as clinical trials conducted by our
collaborators. Forward-looking statements are by their nature
subject to risks, uncertainties and other factors which could cause
actual results to differ materially from those stated in such
statements. Such risks, uncertainties and factors include, but are
not limited to the risks set forth in the Company's most recent
Form 10-K, 10-Q and other SEC filings which are available through
EDGAR at www.sec.gov. The Company assumes no obligation to update
our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-appoints-nadia-agopyan-phd-rac-as-vice-president-of-regulatory-affairs-300901980.html
SOURCE Marker Therapeutics, Inc.